AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10354810 — intervention group
Group type: COMPARATOR
Intervention: Passive viewing into darkness (pDF)
Number of subjects: 0
Study 7492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) analysis of articulatory characteristics for /s, f, tf/
Number of subjects: 10
Study 7492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) analysis of /t/
Number of subjects: 10
Study 7492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) data
Number of subjects: 10
Study 7492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) analysis
Number of subjects: 10
Study 1722310 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant methionyl human granulocyte colony-stimulating factor (r-met-GCSF)
Number of subjects: 10
Study 7045016 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily doses of amoxapine (dosage not specified)
Number of subjects: 35
Study 7045016 — intervention group
Group type: COMPARATOR
Intervention: Divided daily doses of amoxapine (dosage not specified)
Number of subjects: 35
Study 7045016 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine (50 and 100 mg)
Number of subjects: 35
Study 7045016 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 35
Study 7045016 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg)
Number of subjects: 35
Study 31426864 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on 18F-FDG-PET
Number of subjects: 107
Study 28707168 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 28
Study 28707168 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 28
Study 26334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/kg2 iv)
Number of subjects: 15
Study 26334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with Pegintron (1 μg/kg sc)
Number of subjects: 15
Study 26334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with Pegintron and p53 SLP vaccine (0.3 mg/peptide, 9 peptides)
Number of subjects: 15
Study 26334096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 15
Study 24597729 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start
Number of subjects: 3185
Study 22643801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation (Joint Care®) with group therapy, early mobilization (same day as surgery), and 1:1 physiotherapy (2 h/day)
Number of subjects: 147
Study 22643801 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation with individual postoperative care and 1:1 physiotherapy (1 h/day)
Number of subjects: 147
Study 22643801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation
Number of subjects: 147
Study 20070721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) detection using a radioactive tracer and blue dye; followed by radical vulvectomy or radical wide excision with uni/bilateral inguinofemoral lymphadenectomy.
Number of subjects: 23
Study 17317391 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factors (older age)
Number of subjects: 4288
Study 17317391 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factors (pack years smoked)
Number of subjects: 4288
Study 17317391 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factors (systolic blood pressure)
Number of subjects: 4288
Study 17317391 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD treatment (calcium channel blockers)
Number of subjects: 4288
Study 17317391 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factors (self‐reported history of diabetes)
Number of subjects: 4288
Study 17317391 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factors (body mass index)
Number of subjects: 4288
Study 15546229 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement, monitoring, and expectations
Number of subjects: 1320
Study 15546229 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial smoking stage
Number of subjects: 1320
Study 15546229 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial number of friends who smoked
Number of subjects: 1320
Study 15546229 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations over time among smoking stage progression, affiliation with friends who smoke, and parenting behaviors
Number of subjects: 1320
Study 11426631 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐cis‐retinoic acid (9‐cis RA) 100 mg/m2 orally once daily after initial 70 mg/m2 twice a day for the first three patients
Number of subjects: 29
Study 11426631 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐cis‐retinoic acid (9‐cis RA)
Number of subjects: 29
Study 9362390 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of interferon therapy (IFN), 3-5 MU three times weekly
Number of subjects: 79
Study 9362390 — intervention group
Group type: COMPARATOR
Intervention: 6 months of observation followed by 6 months of IFN therapy
Number of subjects: 79
Study 1318845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg
Number of subjects: 16
Study 1318845 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25-50 mg
Number of subjects: 16
Study 4032324 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy (12 sessions)
Number of subjects: 26
Study 4032324 — intervention group
Group type: COMPARATOR
Intervention: Cognitively orientated supportive psychotherapy (6 sessions)
Number of subjects: 26
Study 3237434 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback down-training
Number of subjects: 10
Study 3237434 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback up-training
Number of subjects: 10
Study 30697949 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Facial Pain Expression (IFPE) training
Number of subjects: 54
Study 30697949 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 54
Study 28750893 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE3104
Number of subjects: 0
Study 28750893 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE3165
Number of subjects: 0
Study 28750893 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid buffer
Number of subjects: 0
Study 28750893 — intervention group
Group type: COMPARATOR
Intervention: Human taste assessments
Number of subjects: 0
Study 26727841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14523
Study 26727841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14523
Study 24339936 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 80 kVp and contrast media of 270 mgI/ml with iterative reconstruction algorithm
Number of subjects: 92
Study 24339936 — intervention group
Group type: COMPARATOR
Intervention: Group A: 120 kVp and contrast media of 320 mgI/ml
Number of subjects: 92
Study 20523219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic aspirin therapy
Number of subjects: 11313
Study 20523219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 11313
Study 20523219 — intervention group
Group type: COMPARATOR
Intervention: Chronic antiplatelet therapy (single or dual)
Number of subjects: 11313
Study 18305461 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg
Number of subjects: 102
Study 18305461 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 450 mg
Number of subjects: 102
Study 18305461 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg
Number of subjects: 102
Study 16418843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the left dorsolateral prefrontal cortex
Number of subjects: 0
Study 16418843 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 0
Study 14505767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 0
Study 14505767 — intervention group
Group type: EXPERIMENTAL
Intervention: As-treated analysis
Number of subjects: 0
Study 14505767 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherers-only analysis
Number of subjects: 0
Study 14505767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 0
Study 14505767 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation of missing values
Number of subjects: 0
Study 10752914 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial mattress encasing with a nylon sheet underneath regular cotton bed sheets
Number of subjects: 60
Study 10752914 — intervention group
Group type: COMPARATOR
Intervention: Regular cotton bed sheets (Control Group)
Number of subjects: 60
Study 10752914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon sheet barrier
Number of subjects: 60
Study 10752914 — intervention group
Group type: COMPARATOR
Intervention: Regular cotton bed sheet
Number of subjects: 60
Study 8882988 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase I)
Number of subjects: 48
Study 8882988 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase II)
Number of subjects: 48
Study 1563057 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusions of fentanyl combined with bupivacaine 0.1%
Number of subjects: 0
Study 1563057 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusions of fentanyl alone
Number of subjects: 0
Study 3904394 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 15 mg intravenously, and 50 mg 4 times a day orally (n = 95)
Number of subjects: 190
Study 3904394 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 95)
Number of subjects: 190
Study 31746629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic (1 mU·kg fat‐free mass‐1·min‐1) infusion
Number of subjects: 18
Study 31746629 — intervention group
Group type: COMPARATOR
Intervention: Acute hyperoxia
Number of subjects: 18
Study 31746629 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dopamine (1-4 µg·kg‐1·min‐1)
Number of subjects: 18
Study 31746629 — intervention group
Group type: COMPARATOR
Intervention: Acute hyperoxia + low-dose dopamine
Number of subjects: 18
Study 29356932 — intervention group
Group type: EXPERIMENTAL
Intervention: cTreatment® (new cryotherapy device)
Number of subjects: 97
Study 29356932 — intervention group
Group type: COMPARATOR
Intervention: Standard cold therapy protocol
Number of subjects: 97
Study 27156000 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia Fil® with a nanofilled resin coating (n=515)
Number of subjects: 643
Study 27156000 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX GP® fast with an LC coating (n=486)
Number of subjects: 643
Study 25367242 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 50
Study 25367242 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 50
Study 25367242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 22362136 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D filtered images
Number of subjects: 12
Study 22362136 — intervention group
Group type: COMPARATOR
Intervention: Standard dose images
Number of subjects: 12
Study 22362136 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D filtered images for patients with BMI < 30 kg/m(2)
Number of subjects: 12
Study 19837490 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder of fertilized eggs (Young Tissue Extract; YTE) for four weeks
Number of subjects: 0
Study 19837490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18851750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aneurysmal SAH patients
Number of subjects: 30
Study 18851750 — intervention group
Group type: COMPARATOR
Intervention: Control patients (elective aneurysmal surgery)
Number of subjects: 30
Study 18851750 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Hunt-Hess grades IV to V
Number of subjects: 30
Study 18851750 — intervention group
Group type: COMPARATOR
Intervention: Patients with grade I-III
Number of subjects: 30
Study 16019075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg triamcinolone acetonide
Number of subjects: 12
Study 16019075 — intervention group
Group type: COMPARATOR
Intervention: Posterior Sub‐Tenon's capsule injection of 40 mg triamcinolone acetonide
Number of subjects: 12
Study 16019075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study 12425704 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training (verbal episodic memory; n = 711)
Number of subjects: 2832
Study 12425704 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training (ability to solve problems that follow a serial pattern; n = 705)
Number of subjects: 2832
Study 12425704 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training (visual search and identification; n = 712)
Number of subjects: 2832
Study 12425704 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group (n = 704)
Number of subjects: 2832
Study 10758392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cold blood cardioplegia with 'hot-shot' (CBC)
Number of subjects: 20
Study 10758392 — intervention group
Group type: COMPARATOR
Intervention: Continuous warm blood enriched with esmolol (WBE)
Number of subjects: 20
Study 9190239 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with symptoms of Löfgren syndrome
Number of subjects: 24
Study 9190239 — intervention group
Group type: COMPARATOR
Intervention: Symptomless patients
Number of subjects: 24
Study 9190239 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 24
Study 1283426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril, a phosphorus-containing ACE inhibitor, administered as a prodrug.
Number of subjects: 0
Study 1283426 — intervention group
Group type: COMPARATOR
Intervention: Standard ACE inhibitors that require dosage adjustment due to renal insufficiency.
Number of subjects: 0
Study 3929609 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 gm solution of cefamandole
Number of subjects: 223
Study 3929609 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 223
Study 3929609 — intervention group
Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 223
Study 31201426 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning multiple skills simultaneously (intervention group)
Number of subjects: 42
Study 31201426 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group (Study 1)
Number of subjects: 42
Study 31201426 — intervention group
Group type: COMPARATOR
Intervention: Self-control group (Study 2)
Number of subjects: 42
Study 30699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative vaccination schedule (0-6-50)
Number of subjects: 100
Study 30699272 — intervention group
Group type: COMPARATOR
Intervention: Traditional vaccination schedule (0-2-6)
Number of subjects: 100
Study 30699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 28135975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum group (45g of flaked cereal biscuits daily for 12 weeks)
Number of subjects: 60
Study 28135975 — intervention group
Group type: COMPARATOR
Intervention: White wheat group (45g of flaked cereal biscuits daily for 12 weeks)
Number of subjects: 60
Study 28135975 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sorghum and White Wheat)
Number of subjects: 60
Study 26051348 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) containing 843 mg (‐)‐epigallocatechin‐3‐gallate (EGCG)
Number of subjects: 1075
Study 26051348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study 23536256 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention in home health settings
Number of subjects: 667
Study 23536256 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 667
Study 23536256 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated alert intervention
Number of subjects: 667
Study 20618719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory retraining facial exercises in addition to standard mouth opening exercises
Number of subjects: 186
Study 20618719 — intervention group
Group type: COMPARATOR
Intervention: Standard of care mouth opening exercises after BSSO
Number of subjects: 186
Study 18249230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 10
Study 18249230 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 15904539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 0
Study 15904539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cerebellar lesions (CB)
Number of subjects: 0
Study 15904539 — intervention group
Group type: COMPARATOR
Intervention: Neurologically healthy controls
Number of subjects: 0
Study 12752739 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) with counselling visit
Number of subjects: 0
Study 12752739 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician preference
Number of subjects: 0
Study 12752739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low uncertainty about the decision
Number of subjects: 0
Study 10481420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose in Ringer's acetate solution (2 ml)
Number of subjects: 96
Study 10481420 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine (2 ml)
Number of subjects: 96
Study 10481420 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml) (Control Group)
Number of subjects: 96
Study 8588396 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa 100 to 200 mg
Number of subjects: 28
Study 8588396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1951872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate (500 mg/week)
Number of subjects: 60
Study 1951872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate (1,000 mg/week)
Number of subjects: 60
Study 1951872 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil hydrochloride (200 mg/day)
Number of subjects: 60
Study 1951872 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 60
Study 7035578 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide-protein complex vaccine
Number of subjects: 0
Study 7035578 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 30760231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention (multicomponent intervention including organizational, work environmental, and individual elements)
Number of subjects: 250
Study 30760231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention
Number of subjects: 250
Study 30760231 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 250
Study 27679962 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 27679962 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26391671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) + low-dose ethinyl estradiol (EE) (0.05 mg daily for 5 days)
Number of subjects: 95
Study 26391671 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) + placebo
Number of subjects: 95
Study 23176437 — intervention group
Group type: EXPERIMENTAL
Intervention: Light and moderate alcohol consumption of key participants
Number of subjects: 0
Study 23176437 — intervention group
Group type: COMPARATOR
Intervention: Control group (abstainers)
Number of subjects: 0
Study 21349248 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit measures of liking for nicotine after 12 hours of deprivation
Number of subjects: 0
Study 21349248 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit measures of wanting for nicotine after 12 hours of deprivation
Number of subjects: 0
Study 21349248 — intervention group
Group type: COMPARATOR
Intervention: Implicit measures of wanting and liking for nicotine
Number of subjects: 0
Study 19022694 — intervention group
Group type: EXPERIMENTAL
Intervention: agalsidase beta (Fabrazyme) at 1mg/kg every 2 weeks for up to 5 years
Number of subjects: 134
Study 17355735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg)
Number of subjects: 64
Study 17355735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg)
Number of subjects: 64
Study 17355735 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Dronabinol 10-20 mg, Ondansetron 8-16 mg)
Number of subjects: 64
Study 17355735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17355735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 64
Study 15300183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.1 mg/kg po bid)
Number of subjects: 0
Study 15300183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11372667 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg 17‐beta‐estradiol plus 1 mg norethisterone acetate for 24 months)
Number of subjects: 140
Study 11372667 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 140
Study 11372667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 9566276 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic tetrahydrocannabinol (THC)
Number of subjects: 19
Study 9566276 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study 7536691 — intervention group
Group type: EXPERIMENTAL
Intervention: Radically resected patients
Number of subjects: 233
Study 7536691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypassed patients
Number of subjects: 233
Study 7536691 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with advanced disease
Number of subjects: 233
Study 7536691 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Good risk' bypassed patients (stage I-III)
Number of subjects: 233